Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

Type I interferon is promising in treating different kinds of tumors, but has been limited by its toxicity, lack of tumor targeting, and very short half-life. To target tumors, reduce systemic toxicity, and increase half-life, here we engineer a masked type I IFN-Fc (ProIFN) with its natural recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xuezhi, Liang, Yong, Hu, Zhenxiang, Li, Huiyu, Yang, Jiaming, Hsu, Eric J., Zhu, Jiankun, Zhou, Jin, Fu, Yang-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497482/
https://www.ncbi.nlm.nih.gov/pubmed/34620867
http://dx.doi.org/10.1038/s41467-021-26112-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497482/
https://www.ncbi.nlm.nih.gov/pubmed/34620867
http://dx.doi.org/10.1038/s41467-021-26112-2

Ejemplares similares